Asset
AMBRISENTAN
Gilead Sciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (11)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00768300 | phase3 | terminated | 2008-12-01 | 2011-02-01 | Gilead Sciences | (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF |
| NCT00578786 | phase3 | completed | 2004-02-01 | 2010-03-01 | Gilead Sciences | A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) |
| NCT00423202 | phase3 | completed | 2003-12-01 | — | Gilead Sciences | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. |
| NCT00091598 | phase3 | completed | 2004-01-01 | 2006-02-01 | Gilead Sciences | ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) |
| NCT00879229 | phase3 | terminated | 2009-07-01 | 2011-02-01 | Gilead Sciences | ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 022081 | NDA | GILEAD SCIENCES INC |
Marketed products (2)
- LETAIRIS
- LETAIRIS